Chemical and Analytical Products


Structure Search

  

Shop Online

Screening Compounds
Our present compound collections (US and Abroad) exceeds 450,000+ readily available synthetic organic compounds.

Building Blocks and Intermediates
Our building blocks and intermediates, available from milligram to multi-gram amounts, can also be synthesized in larger quantities upon request.

Reagents
Fine chemicals, biotechnology reagents, buffers, natural products, separation technique products from small quantities up to bulk.

Biotinylation Reagents & Labels
PEG (discrete polyethylene glycol ,dPEG™) crosslinkers, modification reagents and related products are now available from TimTec Inc. dPEG compounds and their derivatives are suitable for wide range of therapeutic, diagnostic, and molecular engineering applications.

Plant Extracts
Our database contains plants collected from various regions of the former USSR with about 2600 available from stock for extraction. Extracts can be prepared on a large scale and fractionated. Active plant component identification is also possible.


Genipin
An excellent natural cross-linker for proteins, collagen, gelatin, and chitosan cross-linking.  

Gossypol and Derivatives
Gossypol is available for large-scale (1, 10, 100 kg) production at our facilities. Unique compounds derived from gossypol are available from stock and for re-supply.

Melittin
Mellitin is natural, non-synthetic, polypeptide from European honey bee, Apis mellifera, venom; the principle hemolytic component. Available from TimTec in custom amounts.

Monastrol
Cell permeable non-tubulin-interacting mitosis inhibitor. Blocks mitosis (IC50=14µM) by binding to the mitotic kinesin Eg5.

2-Chloro-4-nitro Imidazole
2-Chloro-4-nitro Imidazole is available from stock in g/mg amounts and also for large scale synthesis.

PHOTOGEM®
A medicinal preparation against cancer, photosensitizer PHOTOGEM®, the unique medication used in photodynamic therapy (PDT) of malignant tumors of various localizations.

COSMOSIL and COSMOGEL HPLC Columns and Packing Materials
 COSMOSIL HPLC columns provide high efficiency and high-resolution separations. Based on spherical, totally porous silicas COSMOSIL columns offer enhanced chemical and mechanical stability as well as very high surface coverage. COSMOGEL packing materials are non-silica based and provide superior performance in our ion exchange columns.

FlashTube Chromatography Columns
Trikonex FlashTube chromatography is a novel, patented concept for rapid and efficient purification of chemical libraries.

Structure Search Shop Online Download Databases Request a CD
Structure Search eStore Download Request CD

Contact Us

800-574-7391
P: 302-292-8500
F: 302-292-8520

   

Drug Discovery News

  • Osiris Wins Race to Market a Stem Cell Product with Canadian Go-Ahead
    Osiris Therapeutics’ adult stem cell therapy Prochymal® received approval from Health Canada for the treatment of acute graft-vs-host disease (GvHD) in children who failed to respond to steroids. The company will have to carry out certain post-launch confirmatory studies. The decision gives Osiris the distinction of being the first company to win full marketing approval [...]
  • Google Search Engine Forms Basis of Algorithm to Identify Prognostic Cancer Biomarkers
    Scientists have adapted the algorithm used by Google’s web search engine to develop a computational program that can identify panels of biomarkers for cancer prognosis. Google’s PageRank algorithm takes into account the network of hyperlinks between web documents as well as the search terms themselves to determine which pages are most relevant to a particular [...]
  • Janssen Reports Positive Phase III Data for Chronic Diabetic Peripheral Neuropathy Analgesic
    Janssen Pharmaceuticals reported Phase III results demonstrating the efficacy of Nucynta® ER (extended release tapentadol) in managing pain associated with chronic diabetic peripheral neuropathy (DPN). Janssen says the data is consistent with that of a separate study reported in 2011 in patients with DPN. Nucynta ER is a centrally acting analgesic that acts as both [...]
  • Ruga Licenses Selexagen’s RAF Kinase Program for Targeted Cancer Therapy
    Targeted cancer drug developer Ruga negotiated rights to Selexagen Therapeutics’ RAF kinase program. The firm claims the acquired technology addresses the drawbacks to BRAF inhibition as an approach to cancer therapy. Data has demonstrated that BRAF inhibition can actually induce adaptation in RAS-activated cells and promote the development of secondary skin lesions and RAS-mutated tumor [...]
  • Solvo, XenoBiotic to Provide In Vitro Transporter Services in the U.S.
    XenoBiotic Laboratories established a partnership with Hungary-based Solvo Biotechnology to offer in vitro transporter services in the U.S. Solvo will transfer its efflux and uptake transporter assays to XBL’s research facilities in New Jersey. The services will be made available to American customers through both Solvo and XBL sales channels. Through this collaboration Solvo will [...]
  • Affymetrix Launches Circulating Tumor Cell Platform in Deal with ScreenCell
    Affymetrix signed a worldwide distribution agreement for ScreenCell’s isolation devices and dilution buffers for the collection of circulating tumor cells (CTCs) in peripheral blood. The QuantiGene® ViewRNA CTC platform, which consists of ScreenCell’s products and Affymetrix’ QuantiGene ViewRNA Assays, is now available from Affymetrix. The arrangement makes Affymetrix the exclusive distributor of ScreenCell products used [...]
  • Alga Provides Feasible Mass Production System for Subunit Malaria Vaccine Candidate
    An algal system for manufacturing recombinant proteins has provided scientists with the means to generate a malaria-blocking vaccine candidate based on two native unglycosylated Plasmodium falciparum surface proteins, Pfs25 and Pfs28. The University of California, San Diego researchers produced the two P. falciparum proteins in the chloroplasts of the widely used model alga Chlamydomonas reinhardtii, [...]
  • Agilent Acquires Cancer In Vitro Diagnostic Firm Dako for $2.2B in Cash
    Agilent is buying Danish cancer in vitro diagnostics firm Dako for $2.2 billion in cash on a debt-free basis. Agilent says the acquisition is the largest in its history, and will complement its existing life science business and boost its presence in the clinical diagnostics market. “In the rapidly growing diagnostics market, Dako’s products and [...]
  • Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial in RCC
    Aveo Oncology and partner Astellas Pharma Europe reported positive data from the pivotal Phase III study Viro-1, comparing the once-daily oral tyrosine kinase inhibitor candidate tivozanib with sorafenib in 517 patients with advanced renal cell carcinoma (RCC). Astellas says it plans to submit a marketing authorization application for tivozanib to the European authorities during the [...]
  • Evotec Becomes First European CRO to Offer Agilent’s RapidFire Screening Tool
    Evotec is adding Agilent Technologies’ RapidFire mass spectrometry analysis capabilities to its high-throughput screening facilities in Hamburg. RapidFire is an in-line solid-phase extraction technology. It enables ultrafast, direct analysis of native compounds for a variety of biochemical assays including routine ADME and lead discovery applications across a range of therapeutic areas. Evotec reports that it [...]